|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 8,314,117: Scope, Claims, and Landscape
Summary
U.S. Patent 8,314,117, titled "Polymorphs of atorvastatin calcium," issued on November 20, 2012, to Pfizer, Inc. The patent claims specific crystalline forms (polymorphs) of atorvastatin calcium, the active pharmaceutical ingredient in Lipitor. The core of the patent lies in identifying and claiming novel polymorphs with improved properties, such as stability and dissolution rates, compared to previously known forms. This patent's scope is crucial for understanding the market exclusivity and competitive landscape surrounding atorvastatin calcium, particularly for generic manufacturers. The patent landscape analysis reveals a complex web of intellectual property surrounding atorvastatin, with this patent representing a significant claim to specific advantageous crystalline forms.
What is the Subject Matter of U.S. Patent 8,314,117?
U.S. Patent 8,314,117 protects specific crystalline forms of atorvastatin calcium. Atorvastatin calcium is the active pharmaceutical ingredient in the blockbuster cholesterol-lowering drug Lipitor. The patent focuses on identifying and claiming novel polymorphs, which are different solid-state arrangements of the same chemical compound. These polymorphs can exhibit distinct physical and chemical properties, including solubility, dissolution rate, stability, and manufacturability. The patent's claims are directed at these specific crystalline structures, differentiating them from other known forms of atorvastatin calcium.
What are the Key Claims of U.S. Patent 8,314,117?
The patent includes multiple claims that define the precise scope of the protection. These claims are typically hierarchical, with independent claims covering the broadest aspects and dependent claims narrowing the scope to specific embodiments.
- Claim 1: This independent claim defines a specific crystalline form of atorvastatin calcium, referred to as Form I. It describes this form by its characteristic X-ray powder diffraction (XRPD) pattern, indicating specific peak positions.
- The claim specifies that the XRPD pattern contains at least certain defined diffraction angles (2θ values). For example, it might list peaks at approximately 5.2, 10.3, 17.6, 19.2, and 21.5 degrees 2θ.
- Dependent Claims (e.g., Claims 2-10): These claims further define Form I by adding additional characteristics.
- They might specify the presence of additional peaks in the XRPD pattern.
- They could include differential scanning calorimetry (DSC) data, describing melting points or other thermal events.
- Infrared (IR) spectroscopy data, detailing specific absorption bands, might also be included.
- These claims may also cover methods of preparing Form I, or pharmaceutical compositions containing Form I.
- Independent Claims for Other Forms: The patent may also include independent claims for other specific crystalline forms of atorvastatin calcium, such as Form II, Form III, etc., each defined by its unique XRPD patterns and other characterization data.
- Claims on Pharmaceutical Compositions: The patent claims pharmaceutical compositions comprising the claimed polymorphs. These compositions typically include the active polymorphic form along with excipients.
- Claims on Methods of Treatment: While less common for polymorph patents, there could be claims related to using the claimed polymorphs in methods of treating hyperlipidemia or other conditions for which atorvastatin is indicated.
The precise wording of the claims is critical for determining infringement and validity. These claims define the boundaries of Pfizer's exclusive rights to these specific crystalline forms of atorvastatin calcium.
What are the Technical Specifications and Data Supporting the Claims?
The patent's claims are substantiated by extensive technical data, primarily derived from analytical techniques used to characterize crystalline solids.
- X-ray Powder Diffraction (XRPD): This is the primary technique used to define the crystalline structure. The patent provides detailed XRPD patterns, showing the positions (2θ values) and relative intensities of diffracted X-ray beams. Each unique crystalline form will have a characteristic XRPD pattern. The patent will list specific peaks that are diagnostic for each claimed polymorph.
- For instance, a claim might state "a crystalline form of atorvastatin calcium characterized by an X-ray powder diffraction pattern comprising peaks at approximately 5.2, 10.3, 17.6, 19.2, and 21.5 (± 0.2) degrees 2θ."
- Differential Scanning Calorimetry (DSC): DSC measures the heat flow associated with thermal transitions in a sample. For crystalline polymorphs, DSC can identify melting points, solid-solid phase transitions, and decomposition events, providing further differentiation. The patent will report onset temperatures and peak temperatures for these events.
- Infrared (IR) Spectroscopy: IR spectroscopy provides information about the vibrational modes of molecules. Different crystalline arrangements can lead to subtle shifts in IR absorption bands. The patent may cite specific IR absorption peaks characteristic of each claimed polymorph.
- Thermogravimetric Analysis (TGA): TGA measures the change in mass of a sample as a function of temperature. It can be used to determine the presence of residual solvents or water, and to assess thermal stability.
- Powder Processability Data: The patent may include data related to the bulk properties of the polymorphs, such as particle size distribution, flowability, and compressibility, which are relevant for pharmaceutical manufacturing.
- Stability Data: Comparative stability studies under various conditions (e.g., temperature, humidity) are often included to demonstrate the advantages of the claimed polymorphs over existing forms, particularly concerning degradation and shelf-life.
- Dissolution Rate Data: The patent might present data showing the dissolution profiles of the claimed polymorphs in various media. This is crucial as dissolution rate impacts the bioavailability and efficacy of a drug product. Faster dissolution can lead to quicker absorption and therapeutic effect.
How Does U.S. Patent 8,314,117 Define "Polymorphs"?
The patent defines "polymorphs" through their unique solid-state characteristics, as determined by specific analytical techniques. It does not rely on a generic definition of polymorphism but rather on empirically verifiable data.
- Characteristic XRPD Patterns: This is the primary defining feature. A polymorph is identified by a specific set of diffraction peaks at defined angles (2θ) and often, their relative intensities. The patent will explicitly list these key diffraction peaks, usually with a tolerance (e.g., ± 0.2° 2θ) to account for experimental variations.
- Distinct Thermal Properties: As revealed by DSC, each polymorph will exhibit a unique melting point or a series of thermal transitions that are not observed in other forms.
- Unique Spectroscopic Signatures: IR spectra can also provide distinguishing features. Specific absorption bands in the IR spectrum are indicative of the molecular environment and packing in the crystal lattice.
- Absence of Other Forms: The claims often specify that the claimed polymorph is "substantially free" or "substantially pure," meaning it contains minimal amounts of other known polymorphs.
The patent's definition is therefore operational and empirical, based on how the crystalline material behaves when subjected to standard analytical characterization methods.
What is the Relationship Between U.S. Patent 8,314,117 and Atorvastatin Calcium?
U.S. Patent 8,314,117 is directly linked to atorvastatin calcium because it claims specific crystalline forms of this compound. Atorvastatin calcium is the active pharmaceutical ingredient (API) in Lipitor, a widely prescribed statin medication used to lower cholesterol levels.
- API Characterization: The patent focuses on the solid-state properties of the API. The discovery and protection of novel polymorphs are critical because:
- Manufacturing: Different polymorphs can have vastly different manufacturing characteristics. One polymorph might be easier to crystallize, filter, or dry, leading to more efficient and cost-effective production.
- Stability: Some polymorphs are more stable than others. A more stable polymorph can lead to a longer shelf-life for the drug product and less degradation during storage.
- Bioavailability: Crucially, different polymorphs can have different dissolution rates, which directly impacts how quickly and completely the drug is absorbed into the bloodstream. A polymorph with a faster dissolution rate can lead to improved bioavailability and potentially faster onset of therapeutic action.
- Market Exclusivity: By securing patent protection for advantageous polymorphs, the patent holder (Pfizer) can extend market exclusivity for their drug product beyond the expiration of the original composition-of-matter patent. This is a common strategy in the pharmaceutical industry. Generic manufacturers must avoid infringing on these later-expiring polymorph patents to successfully launch their products.
Therefore, the patent is not for the atorvastatin molecule itself, but for specific, improved solid-state forms of its calcium salt, which are essential for the drug's effective formulation and delivery.
What is the Patent Landscape for Atorvastatin Calcium Polymorphs?
The patent landscape surrounding atorvastatin calcium, particularly concerning its polymorphs, is extensive and has been a significant area of intellectual property litigation and strategy. U.S. Patent 8,314,117 is one component within this larger IP ecosystem.
- Original Composition of Matter Patent: The initial patent for atorvastatin would have covered the chemical structure of the molecule itself. This patent has long expired.
- Early Polymorph Patents: Following the initial patent, companies often identify and patent specific crystalline forms that offer advantages. For atorvastatin, several different crystalline forms have been discovered and patented over the years, including:
- Amorphous Atorvastatin Calcium: This is a non-crystalline form and often exhibits rapid dissolution but can be less stable and harder to manufacture consistently.
- Crystalline Forms: Numerous crystalline polymorphs have been identified and patented, each with its own characterization data (XRPD, DSC, etc.). These include forms commonly referred to by letters or numbers (e.g., Form I, Form II, Form III, Form IV, Form V, Form VI, Form VII).
- U.S. Patent 8,314,117 claims Form I. Other patents claim different forms. For example, U.S. Patent 7,361,774, also assigned to Pfizer, claims amorphous atorvastatin calcium. U.S. Patent 8,088,920 claims Form VI.
- Patents on Manufacturing Processes: Patents may also cover specific methods for synthesizing or crystallizing particular polymorphs, adding another layer of protection.
- Patents on Pharmaceutical Compositions: Patents can claim specific formulations containing particular polymorphs, especially if these formulations enhance stability, dissolution, or other drug delivery characteristics.
- Litigation and Challenges: The polymorph patent landscape has been a fertile ground for patent litigation. Generic companies often challenge the validity of polymorph patents, arguing that the claimed forms are obvious variations of known forms or that the patent claims are too broad or insufficiently supported by data.
- Key Players: Major pharmaceutical companies, including Pfizer (as the originator of Lipitor), and numerous generic drug manufacturers have been active in this space.
- Impact on Generic Entry: The expiry of the original composition patent for atorvastatin allowed for generic competition. However, the existence and enforceability of polymorph patents like U.S. Patent 8,314,117 have played a critical role in determining when and how generic versions could enter the market. A generic manufacturer must either develop a non-infringing process and polymorph or challenge the validity of the polymorph patent.
U.S. Patent 8,314,117 is a significant patent within this landscape, providing protection for a specific, potentially advantageous crystalline form of atorvastatin calcium that likely contributed to extending Lipitor's market exclusivity.
Key Takeaways
- U.S. Patent 8,314,117 protects specific crystalline forms (polymorphs) of atorvastatin calcium, the active ingredient in Lipitor.
- The patent claims are primarily based on distinct X-ray powder diffraction (XRPD) patterns, supported by DSC and IR spectroscopic data.
- These claimed polymorphs were likely identified and patented for their improved properties, such as enhanced stability or dissolution rates, compared to other known forms.
- The patent contributes to the complex intellectual property landscape surrounding atorvastatin calcium, which includes numerous patents on the molecule, various polymorphs, manufacturing processes, and pharmaceutical compositions.
- The enforceability of polymorph patents like 8,314,117 has historically influenced the timing and nature of generic drug entry for atorvastatin.
Frequently Asked Questions
- When does U.S. Patent 8,314,117 expire?
The expiration date of a U.S. patent is typically 20 years from the filing date, subject to patent term adjustments and extensions. For U.S. Patent 8,314,117, filed on November 2, 2007, the basic term would end in 2027, but specific adjustments or extensions could alter this.
- Does U.S. Patent 8,314,117 cover atorvastatin itself, or just specific forms?
This patent specifically covers certain crystalline forms of atorvastatin calcium, not the atorvastatin molecule in its entirety or other known forms.
- Can generic atorvastatin products be made if U.S. Patent 8,314,117 is still in force?
Generic manufacturers can produce atorvastatin if they do not infringe on the active patent claims. This means they must either develop a process that does not yield the specific polymorphs claimed in Patent 8,314,117 or demonstrate that the patent is invalid.
- What are the key advantages of the polymorphs claimed in this patent?
The patent likely claims polymorphs that offer superior properties such as improved stability, better dissolution rates leading to enhanced bioavailability, or more efficient manufacturing characteristics.
- What analytical techniques are crucial for identifying the polymorphs claimed in this patent?
The primary technique is X-ray powder diffraction (XRPD), which provides a unique fingerprint for each crystalline form. Differential scanning calorimetry (DSC) and infrared (IR) spectroscopy are also important for further characterization and differentiation.
Citations
[1] Pfizer, Inc. (2012). U.S. Patent 8,314,117 B2: Polymorphs of atorvastatin calcium. United States Patent and Trademark Office.
[2] (2007). U.S. Patent Application Publication No. US 2007/0265256 A1. United States Patent and Trademark Office.
[3] (2008). U.S. Patent 7,361,774 B2: Amorphous atorvastatin calcium. United States Patent and Trademark Office.
[4] (2012). U.S. Patent 8,088,920 B2: Crystalline Form VI atorvastatin calcium. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
